MA41634B1 - Formulation à base de combinaison de tésofensine et de métoprolol - Google Patents

Formulation à base de combinaison de tésofensine et de métoprolol

Info

Publication number
MA41634B1
MA41634B1 MA41634A MA41634A MA41634B1 MA 41634 B1 MA41634 B1 MA 41634B1 MA 41634 A MA41634 A MA 41634A MA 41634 A MA41634 A MA 41634A MA 41634 B1 MA41634 B1 MA 41634B1
Authority
MA
Morocco
Prior art keywords
metoprolol
tesofensin
combination
formulation based
obesity
Prior art date
Application number
MA41634A
Other languages
English (en)
Other versions
MA41634A (fr
Inventor
Peter G Nielsen
Mikael S Thomsen
Bent Højgaard
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of MA41634A publication Critical patent/MA41634A/fr
Publication of MA41634B1 publication Critical patent/MA41634B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une formulation à libération contrôlée comprenant les composés actifs tésofensine et un bêta-bloquant tel que métoprolol ou carvédilol ou leur sel pharmaceutiquement acceptable. L'invention concerne en outre l'utilisation de la formulation à libération contrôlée dans un procédé de traitement du diabète, de l'obésité ou d'un trouble associé à l'obésité.
MA41634A 2015-03-03 2016-03-02 Formulation à base de combinaison de tésofensine et de métoprolol MA41634B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570117 2015-03-03
DKPA201570644 2015-10-09

Publications (2)

Publication Number Publication Date
MA41634A MA41634A (fr) 2018-01-09
MA41634B1 true MA41634B1 (fr) 2021-09-30

Family

ID=55589632

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41634A MA41634B1 (fr) 2015-03-03 2016-03-02 Formulation à base de combinaison de tésofensine et de métoprolol

Country Status (33)

Country Link
US (6) US10231951B2 (fr)
EP (1) EP3265126B1 (fr)
JP (1) JP6772430B2 (fr)
KR (1) KR101999463B1 (fr)
CN (1) CN107666913B (fr)
AU (1) AU2016228002B2 (fr)
CA (1) CA2977415A1 (fr)
CL (1) CL2017002214A1 (fr)
CO (1) CO2017009930A2 (fr)
CR (1) CR20170447A (fr)
DK (1) DK3265126T3 (fr)
DO (1) DOP2017000219A (fr)
EA (1) EA033298B1 (fr)
EC (1) ECSP17059323A (fr)
ES (1) ES2885437T3 (fr)
GT (1) GT201700194A (fr)
HK (1) HK1247127A1 (fr)
HR (1) HRP20211361T1 (fr)
HU (1) HUE055974T2 (fr)
IL (1) IL254179B (fr)
LT (1) LT3265126T (fr)
MA (1) MA41634B1 (fr)
MX (1) MX2017011257A (fr)
PE (1) PE20180187A1 (fr)
PH (1) PH12017501509A1 (fr)
PL (1) PL3265126T3 (fr)
PT (1) PT3265126T (fr)
RS (1) RS62275B1 (fr)
SA (1) SA517382209B1 (fr)
SG (1) SG11201706899VA (fr)
SI (1) SI3265126T1 (fr)
UA (1) UA122224C2 (fr)
WO (1) WO2016138908A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2814473T3 (pl) * 2012-02-16 2019-06-28 Saniona A/S Kompozycje farmaceutyczne do terapii skojarzonej
PT3265126T (pt) 2015-03-03 2021-08-30 Saniona As Formulação combinada de tesofensina e metoprolol
EP3402473A1 (fr) * 2016-01-15 2018-11-21 Saniona A/S Tésofensine et métoprolol pour le traitement de l'hypertension
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (fr) * 2018-07-31 2020-02-06 株式会社親広産業 Promoteur de la consommation de glucose et promoteur de glycolyse
MX2021008208A (es) * 2019-01-07 2021-11-17 Saniona As Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
JP2023523738A (ja) 2020-04-22 2023-06-07 サニオナ エー/エス 視床下部性肥満症の処置
CN117045610B (zh) * 2023-08-24 2024-04-30 杭州沐源生物医药科技有限公司 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016197A1 (fr) 1991-03-18 1992-10-01 Sepracor Inc. Composition et procede contenant du metoprolol optiquement pur (s)
PT885220E (pt) 1996-02-22 2001-11-30 Neurosearch As Derivados de tropano a sua preparacao e utilizacao
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003282375A1 (en) 2003-02-05 2004-08-30 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
WO2005070427A1 (fr) 2004-01-22 2005-08-04 Neurosearch A/S Composes utilises pour perdre du poids de maniere durable
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
DE602006018529D1 (de) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US20090068260A1 (en) * 2006-02-24 2009-03-12 Tomer Gold Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation
US20070202172A1 (en) * 2006-02-24 2007-08-30 Tomer Gold Metoprolol succinate E.R. tablets and methods for their preparation
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
DE102006020604A1 (de) 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
CA2657202A1 (fr) 2006-07-28 2008-01-31 Farmaprojects, S.A. Preparation pharmaceutique de metoprolol a liberation prolongee et son procede de preparation
EP2222302A1 (fr) 2007-11-20 2010-09-01 NeuroSearch A/S Procédé de traitement des troubles d'hyperphagie
WO2009080691A2 (fr) 2007-12-20 2009-07-02 Neurosearch A/S Compositions pharmaceutiques
WO2009080693A2 (fr) * 2007-12-20 2009-07-02 Neurosearch A/S Compositions pharmaceutiques
RU2010131022A (ru) 2007-12-27 2012-02-10 Байер Энимэл Хельс ГмбХ (DE) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЯ СЕРДЦА С ПРИМЕНЕНИЕМ β-БЛОКАТОРОВ
US9408837B2 (en) 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
EP2406253B1 (fr) 2009-03-11 2013-07-03 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. 速効性と持続性を同時に有する薬剤学的組成物
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂
CN102198112A (zh) * 2010-03-26 2011-09-28 北京天衡药物研究院 一种渗透泵型控释片及其制备方法
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
WO2011144975A1 (fr) * 2010-05-15 2011-11-24 Jubilant Life Sciences Limited Compositions multi-unités
WO2012052834A2 (fr) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Système particulaire d'unités multiples comprenant du succinate de métoprolol
CN102085195A (zh) * 2011-01-10 2011-06-08 中国药科大学 琥珀酸美托洛尔缓释片及其制备方法
SG194605A1 (en) 2011-05-06 2013-12-30 Glaxosmithkline Llc Sustained release paracetamol formulations
WO2013001516A1 (fr) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Forme galénique multicouche
CN103906508A (zh) 2011-08-26 2014-07-02 沃克哈特有限公司 治疗心血管疾病的方法
RU2014127884A (ru) 2011-12-09 2016-02-10 Вокхардт Лимитед Способы лечения сердечно-сосудистого нарушения
PL2814473T3 (pl) 2012-02-16 2019-06-28 Saniona A/S Kompozycje farmaceutyczne do terapii skojarzonej
IN2012DE00826A (fr) 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102626396B (zh) * 2012-04-28 2014-05-07 海南华益泰康药业有限公司 一种美托洛尔缓释片剂及其制备方法
EP3019160A1 (fr) 2013-07-09 2016-05-18 Sun Pharmaceutical Industries Ltd Compositions pharmaceutiques à libération prolongée de métoprolol
PT3265126T (pt) 2015-03-03 2021-08-30 Saniona As Formulação combinada de tesofensina e metoprolol

Also Published As

Publication number Publication date
ES2885437T3 (es) 2021-12-13
SI3265126T1 (sl) 2021-11-30
AU2016228002B2 (en) 2020-10-01
US10231951B2 (en) 2019-03-19
HUE055974T2 (hu) 2022-01-28
CL2017002214A1 (es) 2018-04-13
IL254179A0 (en) 2017-10-31
CR20170447A (es) 2018-03-13
HK1247127A1 (zh) 2018-09-21
US9579288B2 (en) 2017-02-28
US20200129478A1 (en) 2020-04-30
EP3265126A1 (fr) 2018-01-10
CN107666913A (zh) 2018-02-06
MX2017011257A (es) 2018-04-10
RS62275B1 (sr) 2021-09-30
EA201791875A1 (ru) 2017-12-29
PH12017501509B1 (en) 2018-02-05
KR20170134393A (ko) 2017-12-06
US10828278B2 (en) 2020-11-10
SA517382209B1 (ar) 2021-04-19
US20160279067A1 (en) 2016-09-29
CA2977415A1 (fr) 2016-09-09
PE20180187A1 (es) 2018-01-23
ECSP17059323A (es) 2018-06-30
KR101999463B1 (ko) 2019-10-01
AU2016228002A1 (en) 2017-09-14
US11426383B2 (en) 2022-08-30
US20180071250A1 (en) 2018-03-15
US12016840B2 (en) 2024-06-25
HRP20211361T1 (hr) 2021-11-26
WO2016138908A1 (fr) 2016-09-09
BR112017018871A2 (pt) 2018-04-17
JP2018507875A (ja) 2018-03-22
PH12017501509A1 (en) 2018-02-05
IL254179B (en) 2020-11-30
LT3265126T (lt) 2021-09-10
US10537551B2 (en) 2020-01-21
PT3265126T (pt) 2021-08-30
US20230092397A1 (en) 2023-03-23
US20210023050A1 (en) 2021-01-28
CO2017009930A2 (es) 2018-01-05
JP6772430B2 (ja) 2020-10-21
SG11201706899VA (en) 2017-09-28
MA41634A (fr) 2018-01-09
EA033298B1 (ru) 2019-09-30
DK3265126T3 (da) 2021-09-13
CN107666913B (zh) 2021-11-26
UA122224C2 (uk) 2020-10-12
EP3265126B1 (fr) 2021-06-02
DOP2017000219A (es) 2018-02-15
PL3265126T3 (pl) 2021-12-06
US20180360804A1 (en) 2018-12-20
GT201700194A (es) 2019-06-12

Similar Documents

Publication Publication Date Title
MA41634B1 (fr) Formulation à base de combinaison de tésofensine et de métoprolol
CL2020002033A1 (es) Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
MA49545B1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
FR3036398B1 (fr) Compositions a base de 1,1,3,3-tetrachloropropene
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MA41138B1 (fr) Formulation à rapport fixe d'insuline glargine/lixisenatide
BR112016026544A2 (pt) métodos para inibir a necroptose
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
CO2020001012A2 (es) Compuestos bifuncionales
MA38816A (fr) Sulfamidase modifiée et sa production
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
WO2015179737A3 (fr) Traitement des affections associées aux éosinophiles ou aux mastocytes
FR3030284B1 (fr) Systeme d'arrimage de securite, mousqueton utilisable pour un tel systeme et ensemble d'arrimage comprenant un tel systeme
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
WO2016140910A3 (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы